Biomarkers in chronic graft-versus-host disease: quo vadis?

D. Wolff, H. Greinix, S. J. Lee, T. Gooley, Sophie Paczesny, S. Pavletic, F. Hakim, F. Malard, M. Jagasia, A. Lawitschka, J. A. Hansen, D. Pulanic, E. Holler, A. Dickinson, E. Weissinger, M. Edinger, S. Sarantopoulos, K. R. Schultz

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Biomarkers are increasingly used for diagnosis and treatment of transplant-related complications including the first biomarker-driven interventional trials of acute graft-versus-host disease (GvHD). In contrast, the development of biomarkers of chronic GvHD (cGvHD) has lagged behind due to a broader variety of manifestations, overlap with acute GvHD, a greater variation in time to onset and maximum severity, and lack of sufficient patient numbers within prospective trials. An international workshop organized by a North-American and European consortium was held in Marseille in March 2017 with the goal to discuss strategies for future biomarker development to guide cGvHD therapy. As a result of this meeting, two areas were prioritized: the development of prognostic biomarkers for subsequent onset of moderate/severe cGvHD, and in parallel, the development of qualified clinical-grade assays for biomarker quantification. The most promising prognostic serum biomarkers are CXCL9, ST2, matrix metalloproteinase-3, osteopontin, CXCL10, CXCL11, and CD163. Urine-proteomics and cellular subsets (CD4+ T-cell subsets, NK cell subsets, and CD19+CD21low B cells) represent additional potential prognostic biomarkers of cGvHD. A joint effort is required to verify the results of numerous exploratory trials before any of the potential candidates is ready for validation and subsequent clinical application.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalBone Marrow Transplantation
DOIs
StateAccepted/In press - Jan 24 2018

Fingerprint

Graft vs Host Disease
Biomarkers
Matrix Metalloproteinase 3
Osteopontin
T-Lymphocyte Subsets
Natural Killer Cells
Proteomics
B-Lymphocytes
Urine
Transplants
Education
Therapeutics
Serum

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Wolff, D., Greinix, H., Lee, S. J., Gooley, T., Paczesny, S., Pavletic, S., ... Schultz, K. R. (Accepted/In press). Biomarkers in chronic graft-versus-host disease: quo vadis? Bone Marrow Transplantation, 1-6. https://doi.org/10.1038/s41409-018-0092-x

Biomarkers in chronic graft-versus-host disease : quo vadis? / Wolff, D.; Greinix, H.; Lee, S. J.; Gooley, T.; Paczesny, Sophie; Pavletic, S.; Hakim, F.; Malard, F.; Jagasia, M.; Lawitschka, A.; Hansen, J. A.; Pulanic, D.; Holler, E.; Dickinson, A.; Weissinger, E.; Edinger, M.; Sarantopoulos, S.; Schultz, K. R.

In: Bone Marrow Transplantation, 24.01.2018, p. 1-6.

Research output: Contribution to journalArticle

Wolff, D, Greinix, H, Lee, SJ, Gooley, T, Paczesny, S, Pavletic, S, Hakim, F, Malard, F, Jagasia, M, Lawitschka, A, Hansen, JA, Pulanic, D, Holler, E, Dickinson, A, Weissinger, E, Edinger, M, Sarantopoulos, S & Schultz, KR 2018, 'Biomarkers in chronic graft-versus-host disease: quo vadis?', Bone Marrow Transplantation, pp. 1-6. https://doi.org/10.1038/s41409-018-0092-x
Wolff, D. ; Greinix, H. ; Lee, S. J. ; Gooley, T. ; Paczesny, Sophie ; Pavletic, S. ; Hakim, F. ; Malard, F. ; Jagasia, M. ; Lawitschka, A. ; Hansen, J. A. ; Pulanic, D. ; Holler, E. ; Dickinson, A. ; Weissinger, E. ; Edinger, M. ; Sarantopoulos, S. ; Schultz, K. R. / Biomarkers in chronic graft-versus-host disease : quo vadis?. In: Bone Marrow Transplantation. 2018 ; pp. 1-6.
@article{ec18d270b1ba437397fe0aff04977bb8,
title = "Biomarkers in chronic graft-versus-host disease: quo vadis?",
abstract = "Biomarkers are increasingly used for diagnosis and treatment of transplant-related complications including the first biomarker-driven interventional trials of acute graft-versus-host disease (GvHD). In contrast, the development of biomarkers of chronic GvHD (cGvHD) has lagged behind due to a broader variety of manifestations, overlap with acute GvHD, a greater variation in time to onset and maximum severity, and lack of sufficient patient numbers within prospective trials. An international workshop organized by a North-American and European consortium was held in Marseille in March 2017 with the goal to discuss strategies for future biomarker development to guide cGvHD therapy. As a result of this meeting, two areas were prioritized: the development of prognostic biomarkers for subsequent onset of moderate/severe cGvHD, and in parallel, the development of qualified clinical-grade assays for biomarker quantification. The most promising prognostic serum biomarkers are CXCL9, ST2, matrix metalloproteinase-3, osteopontin, CXCL10, CXCL11, and CD163. Urine-proteomics and cellular subsets (CD4+ T-cell subsets, NK cell subsets, and CD19+CD21low B cells) represent additional potential prognostic biomarkers of cGvHD. A joint effort is required to verify the results of numerous exploratory trials before any of the potential candidates is ready for validation and subsequent clinical application.",
author = "D. Wolff and H. Greinix and Lee, {S. J.} and T. Gooley and Sophie Paczesny and S. Pavletic and F. Hakim and F. Malard and M. Jagasia and A. Lawitschka and Hansen, {J. A.} and D. Pulanic and E. Holler and A. Dickinson and E. Weissinger and M. Edinger and S. Sarantopoulos and Schultz, {K. R.}",
year = "2018",
month = "1",
day = "24",
doi = "10.1038/s41409-018-0092-x",
language = "English (US)",
pages = "1--6",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Biomarkers in chronic graft-versus-host disease

T2 - quo vadis?

AU - Wolff, D.

AU - Greinix, H.

AU - Lee, S. J.

AU - Gooley, T.

AU - Paczesny, Sophie

AU - Pavletic, S.

AU - Hakim, F.

AU - Malard, F.

AU - Jagasia, M.

AU - Lawitschka, A.

AU - Hansen, J. A.

AU - Pulanic, D.

AU - Holler, E.

AU - Dickinson, A.

AU - Weissinger, E.

AU - Edinger, M.

AU - Sarantopoulos, S.

AU - Schultz, K. R.

PY - 2018/1/24

Y1 - 2018/1/24

N2 - Biomarkers are increasingly used for diagnosis and treatment of transplant-related complications including the first biomarker-driven interventional trials of acute graft-versus-host disease (GvHD). In contrast, the development of biomarkers of chronic GvHD (cGvHD) has lagged behind due to a broader variety of manifestations, overlap with acute GvHD, a greater variation in time to onset and maximum severity, and lack of sufficient patient numbers within prospective trials. An international workshop organized by a North-American and European consortium was held in Marseille in March 2017 with the goal to discuss strategies for future biomarker development to guide cGvHD therapy. As a result of this meeting, two areas were prioritized: the development of prognostic biomarkers for subsequent onset of moderate/severe cGvHD, and in parallel, the development of qualified clinical-grade assays for biomarker quantification. The most promising prognostic serum biomarkers are CXCL9, ST2, matrix metalloproteinase-3, osteopontin, CXCL10, CXCL11, and CD163. Urine-proteomics and cellular subsets (CD4+ T-cell subsets, NK cell subsets, and CD19+CD21low B cells) represent additional potential prognostic biomarkers of cGvHD. A joint effort is required to verify the results of numerous exploratory trials before any of the potential candidates is ready for validation and subsequent clinical application.

AB - Biomarkers are increasingly used for diagnosis and treatment of transplant-related complications including the first biomarker-driven interventional trials of acute graft-versus-host disease (GvHD). In contrast, the development of biomarkers of chronic GvHD (cGvHD) has lagged behind due to a broader variety of manifestations, overlap with acute GvHD, a greater variation in time to onset and maximum severity, and lack of sufficient patient numbers within prospective trials. An international workshop organized by a North-American and European consortium was held in Marseille in March 2017 with the goal to discuss strategies for future biomarker development to guide cGvHD therapy. As a result of this meeting, two areas were prioritized: the development of prognostic biomarkers for subsequent onset of moderate/severe cGvHD, and in parallel, the development of qualified clinical-grade assays for biomarker quantification. The most promising prognostic serum biomarkers are CXCL9, ST2, matrix metalloproteinase-3, osteopontin, CXCL10, CXCL11, and CD163. Urine-proteomics and cellular subsets (CD4+ T-cell subsets, NK cell subsets, and CD19+CD21low B cells) represent additional potential prognostic biomarkers of cGvHD. A joint effort is required to verify the results of numerous exploratory trials before any of the potential candidates is ready for validation and subsequent clinical application.

UR - http://www.scopus.com/inward/record.url?scp=85040938401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040938401&partnerID=8YFLogxK

U2 - 10.1038/s41409-018-0092-x

DO - 10.1038/s41409-018-0092-x

M3 - Article

C2 - 29367715

AN - SCOPUS:85040938401

SP - 1

EP - 6

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

ER -